טוען...
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
PURPOSE: Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies. M...
שמור ב:
| הוצא לאור ב: | Eur J Nucl Med Mol Imaging |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer Berlin Heidelberg
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5397661/ https://ncbi.nlm.nih.gov/pubmed/28280855 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-017-3665-9 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|